Luca Cristiani
Overview
Explore the profile of Luca Cristiani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kroes S, Bierlaagh M, Lefferts J, Boni A, Muilwijk D, Viscomi C, et al.
J Cyst Fibros
. 2024 Nov;
24(1):175-182.
PMID: 39523185
Cystic fibrosis is a life-shortening genetic disease caused by pathological variants of the cystic fibrosis transmembrane conductance regulator gene. The CFTR modulator therapy elexacaftor, tezacaftor and ivacaftor (ETI) rescues CFTR...
2.
Boni A, Cristiani L, Majo F, Ullmann N, Esposito M, Supino M, et al.
Children (Basel)
. 2024 Aug;
11(8).
PMID: 39201852
Cystic fibrosis (CF) is a multisystem disorder characterized by progressive respiratory deterioration, significantly impacting both quality of life and survival. Over the years, lung ultrasound (LUS) has emerged as a...
3.
Cristiani L, Fernandes F
J Cyst Fibros
. 2024 Mar;
23(2):203-207.
PMID: 38431442
This review synthesizes articles published in 2023, focusing on the impact of elexacaftor-tezacaftor-ivacaftor (ETI) in cystic fibrosis (CF) care. Real-world data highlights sustained benefits of ETI across age groups, while...
4.
De Marchis M, Montemitro E, Boni A, Federici A, Di Giovanni D, Cristiani L, et al.
Ital J Pediatr
. 2024 Jan;
50(1):6.
PMID: 38233941
Background: Multiple Breath washout (MBW) represents an important tool to detect early a possible pulmonary exacerbation especially in Cystic Fibrosis (CF) disease. Lung clearance index (LCI) is the most commonly...
5.
Graziano S, Boldrini F, Pellicano G, Milo F, Majo F, Cristiani L, et al.
Chest
. 2023 Nov;
165(4):800-809.
PMID: 37925143
Background: Italy initiated elexacaftor/tezacaftor/ivacaftor (ETI) for people with cystic fibrosis (pwCF) in July 2021. It has led to dramatic improvements in lung function, BMI, sweat chloride, and respiratory symptoms. However,...
6.
Rossitto M, Vrenna G, Tuccio Guarna Assanti V, Essa N, De Santis M, Granaglia A, et al.
J Clin Med
. 2023 Oct;
12(20).
PMID: 37892720
is one of the pathogens most involved in health care-associated infections in recent decades. Known for its ability to accumulate several antimicrobial resistance mechanisms, it possesses the oxacillinase , a...
7.
Gramegna A, Majo F, Alicandro G, Leonardi G, Cristiani L, Amati F, et al.
Respir Res
. 2023 Jun;
24(1):164.
PMID: 37330504
Background: The introduction of the novel therapy, Elexacaftor/Tezacaftor/Ivacaftor (ETI) has been effective in improving weight gain in both clinical trials and real-world studies. However, the magnitude of this effect appears...
8.
Ciciriello F, Bijvelds M, Alghisi F, Meijsen K, Cristiani L, Sorio C, et al.
J Pers Med
. 2022 Apr;
12(4).
PMID: 35455747
Background: The effect of presently available CFTR modulator combinations, such as elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA), on rare CFTR alleles is often unknown. Several assays have been developed,...
9.
La Regina D, Bloise S, Pepino D, Iovine E, Laudisa M, Cristiani L, et al.
Pediatr Pulmonol
. 2020 Nov;
56(1):234-239.
PMID: 33151023
Background: Bronchiolitis is the most common acute viral infection of the lower respiratory tract in infants. Clinical severity is associated with different risk factors; however, no clinical, laboratory, or radiological...
10.
Rossi G, Sacco O, Mancino E, Cristiani L, Midulla F
Infection
. 2020 Aug;
48(5):665-669.
PMID: 32737833
Novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) became pandemic by the end of March 2020. In contrast to the 2002-2003 SARS-CoV outbreak, which had a higher pathogenicity and lead to...